Meeting
2020 Genitourinary Cancers Symposium
Comparative efficacy of local versus systemic salvage therapies for recurrent prostate cancer after primary radiotherapy.
Authors
Glenn Bauman
Western University, London Regional Cancer Program, London, ON, Canada
Glenn Bauman , Keyue Ding , Joseph Chin , Alessandra Iaboni , Laurence Klotz , David P. Dearnaley , Eric M. Horwitz , Juanita M. Crook , Christopher J. O'Callaghan
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Prostate Cancer; Urothelial Carcinoma; Penile, Urethral, Testicular, and Adrenal Cancers
Track
Urothelial Carcinoma,Adrenal Cancer,Penile Cancer,Prostate Cancer - Advanced,Prostate Cancer - Localized,Testicular Cancer,Urethral Cancer
Sub Track
Patient-Reported Outcomes and Real-World Evidence
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr 221)
Abstract #
221
Poster Bd #
A21
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Primary analysis of STARTAR: A phase 2 salvage trial of androgen receptor (AR) inhibition with androgen deprivation therapy (ADT) and apalutamide with radiation therapy (RT) followed by docetaxel in men with PSA recurrent prostate cancer (PC) after radical prostatectomy (RP).
First Author: Tian Zhang
Poster
2020 ASCO Virtual Scientific Program
RTOG 3506 (STEEL): A study of salvage radiotherapy with or without enzalutamide in recurrent prostate cancer following surgery.
First Author: Edwin Melencio Posadas
Poster
2020 ASCO Virtual Scientific Program
Oncological outcomes of 356 patients undergoing salvage focal ablative HIFU or cryotherapy following radiation failure.
First Author: Deepika Reddy
Poster
2024 ASCO Genitourinary Cancers Symposium
Impact of 18F-flotufolastat PET on management of patients with recurrent prostate cancer: Data from the SPOTLIGHT study.
First Author: Przemyslaw Twardowski